专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL269258D0 Methods and compositions for inducing immune responses against clostridium difficile 未知
公开(公告)号：IL269258D0
公开(公告)日：2019-11-28
申请号：IL26925819
申请日：2019-09-10
申请人： NOVAVAX INC , SMITH GALE , LIU YE , TIAN JING HUI , GLENN GREGORY , FLYER DAVID
发明人： SMITH GALE , LIU YE , TIAN JING-HUI , GLENN GREGORY , FLYER DAVID
IPC分类号： A61K20060101
摘要： Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

2. 发明专利

IL257800D0 Vaccine compositions having improved stability and immunogenicity 未知
公开(公告)号：IL257800D0
公开(公告)日：2018-04-30
申请号：IL25780018
申请日：2018-02-28
申请人： NOVAVAX INC , SMITH GALE , LIU YE , TIAN JING HUI , MASSARE MICHAEL , BODDAPATI SARATHI , SHANE ERICA , OLIVER CYNTHIA , GLENN GREGORY
发明人： SMITH GALE , LIU YE , TIAN JING-HUI , MASSARE MICHAEL , BODDAPATI SARATHI , SHANE ERICA , OLIVER CYNTHIA , GLENN GREGORY
IPC分类号： A61K20060101
摘要： Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

3. 发明专利

IL295142A Coronavirus vaccine formulations 未知
公开(公告)号：IL295142A
公开(公告)日：2022-09-01
申请号：IL29514222
申请日：2022-07-27
申请人： NOVAVAX INC , SMITH GALE , MASSARE MICHAEL J , TIAN JING HUI
发明人： SMITH GALE , MASSARE MICHAEL J , TIAN JING-HUI
IPC分类号： A61K39/00 , A61K39/12 , A61P31/14 , C07K14/005
摘要： Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

4. 发明专利

IL277274D0 Multivalent influenza nanoparticle vaccines 未知
公开(公告)号：IL277274D0
公开(公告)日：2020-10-29
申请号：IL27727420
申请日：2020-09-10
申请人： NOVAVAX INC , SMITH GALE , TIAN JING HUI , BODDAPATI SARATHI , HERWADKAR ANUSHREE , WONG JASON , LIN YEN HUEI
发明人： SMITH GALE , TIAN JING-HUI , BODDAPATI SARATHI , HERWADKAR ANUSHREE , WONG JASON , LIN YEN-HUEI
IPC分类号： A61K9/00 , A61K9/51 , A61K39/00 , A61K39/12 , A61K39/145 , A61P31/16
摘要： Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

5. 发明申请

WO02051237A9 HELICOBACTER PROTEINS, NUCLEIC ACIDS AND USES THEREOF 审中-公开
标题翻译： HELICOBACTER蛋白，核酸及其用途
公开(公告)号：WO02051237A9
公开(公告)日：2003-04-17
申请号：PCT/US0148392
申请日：2001-12-07
申请人： ANTEX BIOLOG INC , TIAN JING-HUI , WALKER RICHARD , JACKSON W JAMES
发明人： TIAN JING-HUI , WALKER RICHARD , JACKSON W JAMES
IPC分类号： G01N33/50 , A61K9/50 , A61K9/51 , A61K9/54 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/106 , A61K39/108 , A61K39/112 , A61K39/15 , A61K39/39 , A61K39/395 , A61K45/00 , A61K48/00 , A61P31/04 , A61P37/04 , C07K14/195 , C07K14/205 , C07K16/12 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/31 , G01N33/15
CPC分类号： C07K14/205 , A61K39/00 , A61K48/00 , A61K2039/505 , A61K2039/53 , C07K2319/00
摘要： The invention discloses Helicobacter HP30 or HP56 polypeptide, polypeptides derived thereof (HP30-derived or HP56-derived polypeptides), nucleic acids encoding said polypeptides, antibodies that specifically bind the HP30, HP56, HP30-derived or HP56-derived polypeptides and T cells specific for HP30, HP56, HP30-derived or HP56-derived polypeptide. Also disclosed are prophylactic or therapeutic compositions, including immunogenic compositions, e.g. vaccines, comprising HP30, HP56, HP30-derived or HP56-derived polypeptides, nucleic acids encoding the same or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Helicobacter cells or antigens.
摘要翻译：本发明公开了幽门螺杆菌HP30或HP56多肽，其衍生的多肽（来自HP30的或HP56衍生的多肽），编码所述多肽的核酸，特异性结合HP30，HP56，HP30衍生的或HP56衍生的多肽和T细胞特异性的抗体用于HP30，HP56，HP30衍生的或HP56衍生的多肽。还公开了预防或治疗组合物，包括免疫原性组合物，例如，包含HP30，HP56，HP30衍生的或HP56衍生的多肽的疫苗，编码它们的核酸或其抗体。本发明另外公开了在动物中诱导对幽门螺杆菌细胞或抗原的免疫应答的方法。

6. 发明申请

WO02051237A3 HELICOBACTER PROTEINS, NUCLEIC ACIDS AND USES THEREOF 审中-公开
标题翻译： HELICOBACTER蛋白，核酸及其用途
公开(公告)号：WO02051237A3
公开(公告)日：2004-02-26
申请号：PCT/US0148392
申请日：2001-12-07
申请人： ANTEX BIOLOG INC , TIAN JING-HUI , WALKER RICHARD , JACKSON W JAMES
发明人： TIAN JING-HUI , WALKER RICHARD , JACKSON W JAMES
IPC分类号： G01N33/50 , A61K9/50 , A61K9/51 , A61K9/54 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/106 , A61K39/108 , A61K39/112 , A61K39/15 , A61K39/39 , A61K39/395 , A61K45/00 , A61K48/00 , A61P31/04 , A61P37/04 , C07K14/195 , C07K14/205 , C07K16/12 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/31 , G01N33/15 , A61K39/02
CPC分类号： C07K14/205 , A61K39/00 , A61K48/00 , A61K2039/505 , A61K2039/53 , C07K2319/00
摘要： The invention discloses Helicobacter HP30 or HP56 polypeptide, polypeptides derived thereof (HP30-derived or HP56-derived polypeptides), nucleic acids encoding said polypeptides, antibodies that specifically bind the HP30, HP56, HP30-derived or HP56-derived polypeptides and T cells specific for HP30, HP56, HP30-derived or HP56-derived polypeptide. Also disclosed are prophylactic or therapeutic compositions, including immunogenic compositions, e.g. vaccines, comprising HP30, HP56, HP30-derived or HP56-derived polypeptides, nucleic acids encoding the same or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Helicobacter cells or antigens.
摘要翻译：本发明公开了幽门螺杆菌HP30或HP56多肽，其衍生的多肽（来自HP30的或HP56衍生的多肽），编码所述多肽的核酸，特异性结合HP30，HP56，HP30衍生的或HP56衍生的多肽和T细胞特异性的抗体用于HP30，HP56，HP30衍生的或HP56衍生的多肽。还公开了预防或治疗组合物，包括免疫原性组合物，例如，包含HP30，HP56，HP30衍生的或HP56衍生的多肽的疫苗，编码它们的核酸或其抗体。本发明另外公开了在动物中诱导对幽门螺杆菌细胞或抗原的免疫应答的方法。

7. 发明申请

WO2017041100A3 VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY 审中-公开
标题翻译：疫苗组合物具有改善的稳定性和免疫原性
公开(公告)号：WO2017041100A3
公开(公告)日：2017-04-20
申请号：PCT/US2016050413
申请日：2016-09-06
申请人： NOVAVAX INC
发明人： SMITH GALE , LIU YE , TIAN JING-HUI , MASSARE MICHAEL , BODDAPATI SARATHI , SHANE ERICA , OLIVER CYNTHIA , GLENN GREGORY
IPC分类号： A61K39/155 , A61K9/00
CPC分类号： A61K39/155 , A61K9/0019 , A61K9/1611 , A61K9/1617 , A61K39/12 , A61K2039/54 , A61K2039/55505 , A61K2039/55555 , C12N7/00 , C12N2710/14143 , C12N2760/14134 , C12N2760/14171 , C12N2760/16122 , C12N2760/16134 , C12N2760/16151 , C12N2760/16222 , C12N2760/16234 , C12N2760/16251 , C12N2760/18522 , C12N2760/18534
摘要： Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
摘要翻译：本文公开了适用于疫苗的纳米颗粒。纳米颗粒呈递来自病原体的抗原，其被清洁剂核心包围并与其相缔合，从而导致增强的稳定性和良好的免疫原性。还公开了用于制备疫苗和纳米颗粒的剂量，制剂和方法。

8. 发明专利

SG11201908376UA METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AGAINST CLOSTRIDIUM DIFFICILE 未知
公开(公告)号：SG11201908376UA
公开(公告)日：2019-10-30
申请号：SG11201908376U
申请日：2018-03-15
申请人： NOVAVAX INC
发明人： TIAN JING-HUI , LIU YE , SMITH GALE , GLENN GREGORY , FLYER DAVID
IPC分类号： A61K39/00 , A61K39/08 , A61K39/39
摘要： MolWE: ,312 Mature CDTb (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT Iiiimmomiolollmonolomolomolimillomoiflomom (10) International Publication Number WO 2018/170238 A2 (51) International Patent Classification: A61K 39/08 (2006.01) (21) International Application Number: PCT/US2018/022597 (22) International Filing Date: 15 March 2018 (15.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/471,636 15 March 2017 (15.03.2017) US 62/474,434 21 March 2017 (21.03.2017) US (71) Applicant: NOVAVAX, INC. [US/US]; 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). (72) Inventors: TIAN, Ting-Hui; c/o Novavax, Inc., 20 First- field Road, Gaithersburg, Maryland 20878 (US). LIU, Ye; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). SMITH, Gale; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). GLENN, Gregory; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). FLYER, David; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). (74) Agent: TUSCAN, Michael et al.; Cooley LLP, 1299 Penn- sylvania Avenue, N.W., Suite 700, Washington, District of Columbia 20004-2400 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AGAINST CLOSTRIDIUM DIFFICILE Fig. 1: C. difficile triple toxin vaccine constructs Triple toxin 1420 CDTb Mature CDTb Tcca RBD cc O N 00 O C iRARRRKKR With a Turin cleavage site Mal Wt: 206,421 Triple toxin 1470 (57) : Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection. [Continued on next page] WO 2018/170238 A2 IMIOH01101 DIVIRE1013311011010111OH11111i# TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a))

9. 发明专利

AR121151A1 FORMULACIONES PARA VACUNA CONTRA CORONAVIRUS 未知
公开(公告)号：AR121151A1
公开(公告)日：2022-04-20
申请号：ARP210100201
申请日：2021-01-27
申请人： NOVAVAX INC
发明人： SMITH GALE , MASSARE MICHAEL J , TIAN JING-HUI
IPC分类号： A61K39/215 , A61P31/14 , C07K14/165 , C12N15/50
摘要： En el presente documento se divulgan proteínas de la espícula (S) de coronavirus y nanopartículas que las comprenden, que son adecuadas para su uso en vacunas. Las nanopartículas presentan antígenos de patógenos rodeados y asociados con un centro detergente, que da como resultado una estabilidad potenciada y buena inmunogenia. También se divulgan dosificaciones, formulaciones, y métodos para preparar las vacunas y nanopartículas.

10. 发明专利

SG11202009206QA MULTIVALENT INFLUENZA NANOPARTICLE VACCINES 未知
公开(公告)号：SG11202009206QA
公开(公告)日：2020-10-29
申请号：SG11202009206Q
申请日：2019-03-19
申请人： NOVAVAX INC
发明人： BODDAPATI SARATHI , HERWADKAR ANUSHREE , WONG JASON , LIN YEN-HUEI , SMITH GALE , TIAN JING-HUI
IPC分类号： A61K39/145 , A61K39/155 , A61K39/295 , C12N7/00
摘要： Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式